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ABSTRACT:  
 
This paper presents an approach to evaluating the potential supply chain benefits of adopting continuous 
processing technologies for a diverse set of pharmaceutical products. The approach integrates upstream 
‘continuous’ processing considerations for the production of active ingredients and final product formulation, with 
the downstream implications for packing and distribution. Currently, these upstream and downstream operations 
largely operate as decoupled operations with independent coordination and governance mechanisms, and the 
approach presented in this paper identifies opportunities for more case-specific integrated end-to-end supply 
chains enabled by continuous flow technologies. Three specific product (and corresponding processing 
technology) case studies are used to demonstrate the utility of the approach in assessing the supply network and 
system integration opportunities that emerge from the continuous processing of pharmaceutical products. 
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1. INTRODUCTION 
 
In many industries, supply chains have become ‘disaggregated’, with activities spread across multiple firms and 
locations, with individual manufacturing sites increasingly geographically distributed.  In Pharmaceuticals, this 
specialisation has been heavily influenced by the separation of unit operations between the discrete steps of 
Active Pharmaceutical Ingredient (API), Primary Product Formulation, Secondary Pack Processing, and 
Distribution activities. Indeed within each of these manufacturing supply chain stages, the predominance of batch 
processing models has meant that existing pharmaceutical supply chains operate in a high inventory, slow 
response environment. Traditionally, manufacturing supply network design has involved integrating these 
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discrete manufacturing activities but has been constrained by the fact key unit operations are run in batch 
processing modes. However, continuous flow technologies, present new opportunities to the network designer as 
radically reconfigured supply networks, with genuine flow-through capabilities through to the end-user, become 
genuine possibilities [1]. In this paper, we develop an approach to assessing the potential for the continuous 
processing of pharmaceutical products, including specific implications of defined technology developments for 
three case studies. Thus, potential users of the methodology will include supply chain designers, future product 
process-engineering developers and those involved in new product business appraisal. The technology focus of 
each of the case studies is in: 
  
 Case 1 – Anti-retrovirals (ARVs): Firstly, on particle size control and continuous crystallisations to 
enable better API quality control (especially for high drug loading products). In addition, continuous 
formulation advances are used to manage the high complexity of product variants, which is a defining 
characteristic of the product group. The case, therefore, also incorporates considerations on supply 
models, as case 1-type drug products often tend to be ‘made-to-order’. This has led to longer lead times 
and an inability to meet emergency orders when minimum batch size requirement (5,000 packs) have 
resulted in 8 month delays between initial orders and initial production for low volume, niche derivatives 
[2]. 
 Case 2 – Anti-malarial Artemisinin Combination Therapies (ACTs): continuous synthesis to reduce 
solvent use (which is a major issue in the current, low yield batch extraction process), reduce lead times 
and lower production costs. Here, continuous technology ‘interventions’, from synthesis right through to 
packaging and labelling, have been considered in developing and assessing a series of alternative 
supply models [3]. 
 Case 3 – Diabetes drug, such as Metformin: addressing the need for significant additional capacity, 
based on future trends, where volume projections suggest a doubling of demand by 2035. Here, utilising 
continuous granulation, and moving towards significantly smaller plant footprints with associated capital 
cost reductions are commercially attractive [1]. 
 
 
Research on the disaggregation of value chains has tended to consider ‘industry sectors’ as their unit of analysis 
where changes to industry structure in for example, computing [4] and financial services [5] has been driven by 
trends in outsourcing and off-shoring which continue to shape modern manufacturing networks.  
Within this industry focus, different patterns of specialisation have been identified as firms seek to integrate new 
external capabilities and capture location benefits [6], [7], [8]. Mudambi and Venzin [9] introduce technology as a 
key analytical approach to how networks evolve.  Within healthcare, and specifically in-vitro diagnostics, the 
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disaggregation of value networks has been analysed from an emerging technology context [10]; the healthcare 
context providing radically different patient-centric supply chain models and potentially novel business models.  
 
From a theoretical perspective, supply chain analysis and design requires a focal firm perspective of an extended 
network of firms across a defined product category. However, the optimum configuration of these increasingly 
complex and fragmented networks is particularly challenging where there are ‘multiple tiers’ of partner firms, 
spanning component and intermediate goods supply, presenting a multitude of options on location and partnering 
models [11], [12].  These supply networks comprise of semi-independent sub-systems that have then become 
part-disconnected with independent governance mechanisms. These sub-systems can, over time frustrate the 
operation of integrated outcome based supply chains. For these complex multi-tier supply networks, the more 
holistic approach presented here considers the industrial system design activity as an integrating process that 
spans the discrete sub-systems that make up the end-to-end supply chain.  
 
 
2. NETWORK SYSTEMS ANALYSIS AND INTEGRATION OF SUB-SYSTEMS 
 
The methodology that is presented here builds on cross-sector observations of complex multi-tier supply 
networks where sub-systems have evolved as discrete entities [12], and an underlying premise that a whole 
systems perspective can support a re-examination of end-to-end network design. A re-configuration of the 
network requires identification of the drivers of, and interactions between, the main sub-systems in these 
complex, multi-tier supply networks.  The attractiveness of applying the sub-systems integration approach will 
arise in multi-tier supply networks where the production of intermediate goods, as discrete sub-systems, has 
emerged as a mechanism for the effective organisation of the current industrial system. In Consumer Electronics 
for example, global scale contract manufacturers now dominate the sector, supplying key components and/or 
providing final assembly operations. In Aerospace, major component supply chains have emerged that operate 
as discrete entities; the UK for example is No.2 globally in aerospace manufacture without major final assembly. 
Intermediate goods supply chains are also prevalent in the textile sector where opportunities for supply network 
development involve re-integration of discrete operations, with some manufactures considering closed loop 
supply chains to optimise resource re-use. These reconfiguration options are invariably driven by technology 
changes.   
 
However, in most sectors sub-systems operate as independent units targeting internal efficiencies, functioning as 
silos of activity, mirroring the functional units seen in large organisations. This internal sub-system focus can 
work to the detriment of the end-to-end supply network. In highly regulated environments, regulation can 
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inadvertently ‘lock-in’ this structural development and frustrate end-to-end supply chain optimisation. In 
Pharmaceuticals, the sub-system of clinical supply often imposes production process and consequent regulatory 
constraints for the commercial supply chain.  
 
The reconnecting of semi-isolated sub-systems presents opportunities for an end-to-end supply network 
perspective, connecting upstream and downstream elements. This approach to supply network integration and 
optimisation can inform the product-process technology agenda. Alternative production processing models would 
target system outcomes that aim to address sub-system constraints, redefining supply network drivers of network 
performance. Examples of alternative processing models that might support more ‘flow-through’ end-to-end 
operations include continuous-processing and crystallisation in previously batch-process-oriented Pharma, 
additive manufacturing in engineering component manufacture that replaces traditional subtractive processes 
(e.g. aero-engine casings are now manufactured at the point of final assembly rather than being produced in 
three separate locations before being shipped to the assembly site), and late product post-dosing finishing 
models that enable more near-market supply (e.g. in FMCG post dosing used for variant production with reduced 
lead times; industrial ceramics continuous inkjet variant production in Europe to satisfy SKU proliferation 
demands [1]). Each of these alternative supply chain models have required significant technology breakthroughs 
to enable a broader industrial systems optimisation agenda, enabling radically different product quality and/or 
flexibility (volume, variety) opportunities, potentially enabling previously elusive markets to be served 
economically. 
 
In this research, we develop an approach to evaluate the system level business opportunities that arise from the 
continuous processing of pharmaceutical products. To demonstrate the utility of the approach, the three different 
cases are considered to evaluate the relative benefits of continuous processing.  
 
 
3. METHODOLOGY DEVELOPMENT – PHARMA CONTEXT 
 
While evidence exists for continuous processing delivering financial benefits (mainly for single-purpose plants), 
these studies have largely been focused at the production and plant level [13], [14], [15], [16] with the overall 
business case in each case lacking an end-to-end supply network assessment. These case studies are 
discussed briefly later in this section. 
 
The approach to network design and systems integration extends prior work on industrial systems analysis and 
supply chain mapping techniques [10],[11],[17] . It involves identifying the drivers of, and interactions between, 
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the main sub-systems across the supply network. System boundaries are extended to encompass the end-user, 
and used to inform potential sub-system trade-offs. A key requirement involves ‘technology experts’ to evaluate 
alternative supply network configuration models.  
 
From an end-to-end supply network perspective, four proposed stages of analysis are summarised below;  
 
i. Identifying barriers and opportunities to adopting alternative product-process technologies  
Barriers may be real or perceived and arise from combinations of socio-political, technical and 
regulatory factors.  
 
Despite such barriers to adoption, there is growing evidence, within industrial setting, that firms are 
moving towards significant adoption of continuous processing, some examples of which are outlined in 
table 1.  
 
 
 
Table 1. Summary of companies with significant investments in continuous processing 
 
 
 
 
In addition, the academic literature has also reported studies where continuous processing has been 
shown to have an advantage over batch, in terms of process, economics and volumes. 
 
In their study comparing continuous and batch reactors with respect to nitration and hydrogenation 
reactions, Calabrese et al. [13] observed a drastic reduction in the hydrogenation reaction, from 10h to < 
2 minutes, when run in continuous flow.  This resulted in overall cost reduction potential, through 
reduction of catalyst and the smaller equipment footprint required. In their 2007 study, Roberge et al. 
[14] studied the economics of three hybrid systems, involving campaigns producing 5 tonnes of an 
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isolated intermediate through a multi-stage reaction. It was demonstrated that the best result was found 
when all of the reaction steps were transferred to a continuous-flow operation. This enabled a potential 
decrease from 3.5 to 2.0 operators per shift and a 16% economic gain when all reactions were 
transferred from batch to continuous flow operations.  In addition, Gorsec and Glavic [15] compared 
continuous and batch operation modes on the basis of economic evaluation and found that the 
continuous plant is more profitable than batch for all capacities (from 200 tonnes/annum) in the case of 
single purpose equipment. Finally, in this section, in a batch multi-product plant versus continuous 
single-product plant study in 2012 (for the production of proteins), Seifert et al. [16] benchmarked four 
continuous mono-product plants against a multi-product batch plant, for the production of proteins, at 
volumes in the range of 1,500-6,000 kg/annum.  It was demonstrated that a change from batch to 
continuous operation resulted in a > 30% higher net present value at the end of the operating period 
(i.e. net present value of an investment here tells how a continuous investment compares versus that of 
the current state batch process) 
 
A number of global initiatives have been commissioned to take on elements of the continuous 
processing transformation challenge. For example, in technology development, programmes are already 
underway that are required in continuous manufacturing. These include a UK Centre for Continuous 
Manufacturing and Crystallisation (CMAC), a US-based Novartis-MIT Center for Continuous 
Manufacturing, the US Centre for Structured Organic Particulate Systems (cSOPS), Ireland SSPC 
(Synthesis and Solid State Pharmaceutical Centre), various European consortia, and several prototype 
equipment developments (e.g., UK CMAC Research Partnership Investment Fund). More recently, a 
new initiative to developing an E2E Supply Chain “eco-system” that considers technology developments 
(including continuous processing developments) within new supply chain models and the appropriate 
regulatory regimes required at an industry sector level have been commissioned (UK ReMediES 
project) [1].  
 
In terms of an end-to-end assessment, volume and complexity are two key discriminating variables (in 
many product sectors/categories) that can influence supply network design [25]. In the context of this 
study, figure 1 sets out, at a conceptual level the opportunity in the batch-continuous context for 
particular processing models, e.g. 
 
Position A on the chart focuses on unmet patient needs and affordability for low volume and 
high variant products. In this space, alternative processing models may be used to serve 
existing markets more effectively or those that have been previously considered uneconomical 
 7 
to serve (delivering unmet end-user needs) driven by new capabilities that create new markets. 
Personalised medicines or niche product markets exemplify patient populations where 
advances in diagnostics, information technologies and digitisation, are enabling more 
disaggregated value network models. The argument here is that micro-continuous processing 
may offer solutions and this is being actively pursued by several research centres e.g. CMAC. 
 
 
 Position B at the centre captures the space where both batch and continuous processing could 
feasibly work. Here, batch processing may still retain cost advantages over continuous at 
certain volumes and SKU mixes. 
 
 Position C captures opportunities in terms of cost, flexibility or reliability, where continuous 
processing may offer advantages over batch at specific higher volumes. 
 
Note: The three positions A, B and C do not relate to the three case studies that are evaluated in section 
4, but represent (at a conceptual level) where continuous processing may be beneficial (positions A and 
C) and where batch may still be the preferred production model (position B). 
 
 
          
 
 
Figure 1 Conceptualising the Volume-Variety Matrix in Pharma, adapted from [25] 
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ii. Sub-system identification and analysis; comparison with an end-to-end systems perspective   
Current-state supply and value network mapping techniques are used to define the existing sub-
systems and the drivers/design factors that predominate in each sub-system. A schematic 
representation of a typical ‘current-state’ processing model for pharmaceutical production is presented 
in figure 2. In reality, this process model will vary case-by-case with some processing activities not 
required and additional processing steps necessary. Once the current state has been mapped for a 
specific case, alternative continuous technology processing options and their technology readiness 
levels may be assessed. An end-to-end network performance analysis is then used to define overall 
system metrics in order to re-examine these semi-independent sub-systems, challenging the current 
state configuration design parameters and trade-offs being made.  
 
 
 
Figure 2 – Schematic of a typical ‘current-state’ production processing model for pharmaceuticals,  
Here n = number of repetitions; each repetition may involve a variation in sequence of steps; steps may also 
consist of linear and/or convergent synthetic routes 
 
 
iii. Alternative supply network scenario analysis/development 
Supply network scenarios that could emerge by adopting alternative product-process configurations and 
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business model innovations are evaluated. Alternatives process and production technologies may be 
based on emerging technologies or technologies that are still yet to be fully proven or developed but 
where a supply network assessment identifies system benefits that would emerge from a more ‘flow-
through’ operation. 
 
In Pharmaceuticals, emerging technologies may be primary production technology based, such as 
continuous processing and crystallisation of APIs, or secondary continuous processing of final product 
formulations, or driven by novel routes to market driven by next generation diagnostics. These 
alternative scenarios may support very different scale production operations, i.e. rather than the large 
one-size fits all batch plants of today, consideration of dispersed, close-to-market, low-scale integrated 
plants may be possible through new production technologies. Alternative downstream supply models 
might also be possible due to advances in patient diagnostics, product re-ordering models or direct 
replenishment, enabled by e-commerce-based last-mile supply chains. In practice, scenarios depend on 
various disruptive influences that challenge the current value network model and introduce new 
possibilities to product or product-service models.    
 
 
iv. Systems Analysis Analytical Framework 
Finally, an end-to-end supply network systems analysis is undertaken. This process evaluates the 
alternative scenarios under consideration and how they might redefine existing sub-systems as part of 
an integrated systems/network re-configuration agenda. The approach involves the assessment of 
potential benefits of promising scenarios, as a ‘delta’ analysis on the current state against key system 
metrics. Whereas system benefits may accrue, the value proposition in making the transformation for 
key supply network partners is assessed from a business context. For example, the potential impact on 
revenue, margin, inventory reduction etc, against the investments required, and the technological 
feasibility of the identified disrupted scenario. These elements of the evaluation are incorporated into a 
total systems/network analytical framework. 
 
In this paper, we set out the criteria used in each stage of the analysis process, and demonstrate the application 
of the analytical framework for three pharmaceutical products where ‘alternative’ continuous processing 
technologies are being considered.  
 
The Pharmaceutical sector was chosen as it faces multiple challenges; affordability of drugs that question the 
viability of current operating models, ageing populations that require new approaches to patient care, and major 
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technology advances in therapeutics and production technologies, changes that have the potential to generate 
very different supply network configurations with increasingly distributed information flows and revenue models 
[1],[26]. The sector also exhibits the criteria of a multi-tier supply network with very well established and 
independently managed sub-systems of active production, formulation, and final pack, with extended distribution 
models. Material resource efficiency end-to-end is poor with low patient compliance, compounded by waste in the 
production process, with moderate production process quality performance (typically 3 sigma). From a product 
life cycle perspective, Clinical trial supply chains are also typically managed separately from the full-scale 
commercial supply chains. Regulatory and governance frameworks map these separate and established batch-
process operating models. National governments are increasingly reluctant to accept the cost of new drugs whilst 
the major primes are managing a more fragmented product portfolio as new technologies are driving smaller 
volume production runs targeting more niche markets. At a network systems level, the sector suffers from 
excessively high inventory levels (c. 18 months end-to-end) and slow response to changes in market demand [1], 
[26], [27], [28].  
 
4. CASE STUDY ANALYSIS  
 
The pharmaceutical cases that were chosen represent products at different stages of their product life cycle, 
have dissimilar product volume and pack complexity profiles, and varying transformation challenges if the 
alternative process supply network and business case is implemented.  
 
The three cases for taking through the analytical process represent; 
 Annual volume ranges that span (1) <<100 tonnes, (2) mid-range volumes (200-300 tonnes), and (3) 
volumes substantially > 10,000 tonnes 
 Products that have (1) high levels of unique product and SKU variants, (2) represent a growing number 
of derivatives and SKUs and  (3) modest SKU variants, that emerge from single API multiple 
dose/format combinations, or multiple API and variant dose/format combinations 
 Credible continuous processing options from a chemistry and chemical engineering unit operations 
perspective  
 Reconfiguration drivers that consider both operational and societal benefits   
The rationale for each of the selected cases products is further defined in Figure 3, with supporting drivers for 
change, reported in Table 2. 
For each of these products the stage-wise analysis process conducted and findings are described below; 
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(i) Identifying barriers and (system-level) opportunities to adopting alternative product-process 
technologies for specific cases 
The first stage of the analysis considers the potential end-user markets where continuous processing technology 
might provide additional volume or variant opportunities, in terms of business and/or societal benefits. This may 
involve delivering unmet user needs (e.g. low volume, niche markets previously unviable) and/or operational 
variant flexibility benefits, or cost benefits through increased scale. 
 
 
   
Figure 3 – Volume-product variety profiles for the three specific product-process cases  
 
 
For each of the three cases, system level barriers and opportunities that might result from adopting more 
continuous processing are considered from multiple perspectives; new patient populations, government health 
service providers, and industrial network partners.  
 
(ii) Sub-system identification and analysis; comparison with an end-to-end systems perspective 
 
In this second stage of the analysis, ‘current-state’ configuration mapping and basic product-life cycle tools are 
used to identify the sub-systems across the total supply/value network. The following sub-systems were identified 
within the Pharmaceutical product sector; Clinical trial Supply Chain process; Primary and Secondary 
Manufacture, Packing and downstream Distribution. 
 
The specific research questions to be addressed in terms of system optimisation, factors of analysis, and desired 
outcome across these subsystems were defined as follows; 
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• What are the potential patient populations (volume/variety) including unmet needs that are pre-disposed to 
continuous processing? 
• How does continuous processing optimise overall revenue, lead time, investment (and risk) for the target 
product timeline?  
• What are the viable and attractive product-process archetypes and configurations that match target patient 
populations and manageable product portfolios, and shorten processing cycle times?  
• How to better configure a demand driven pack supply chain that match target patient populations and 
manageable product portfolios? 
• What are the new supply network and business models that might emerge from continuous technologies and 
processes?  
 
For each of the case product groups, technical experts were used to collate standard operational data, current 
and alternative/future processing scenarios, and wider ‘societal-importance’ considerations that may influence 
the reconfiguration opportunity. Societal importance is based on developing the case for delivering more 
affordable drugs, meeting unmet needs or addressing new patient populations.. 
 
The results from this stage of the analysis are set out in Table 2 below. 
 
 
(iii) Alternative supply network scenario analysis/development 
In Table 2, an initial assessment of future/alternative processing models was conducted where alternative 
chemical process scenario analysis considered opportunities for more flow-through continuous processing. 
These scenarios are then evaluated in terms of the ‘delta’ or relative benefits against key system level 
operational benefits that might emerge from continuous processing. This step in the process generates ‘the delta’ 
or potential step change possibilities in the key metric(s) or impact variable under consideration (see table 3) 
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Table 2 Analysis of Supply Network Operational Parameters 
 
Note. 
Case 1 (HIV) is supported by industrial practice/interviews and secondary referenced data sources.  
Case 2 (Malaria) assertions are based on specific design calculations, corroborated by secondary data sources and industrial 
practice/interviews.  
Case 3 is based on secondary data and supported by industrial practice/interviews. 
Appendix A sets out the expert informants, by role, and their contribution to the 3 cases 
 
 
 
 
 
 
 
 
Data set  Parameters Case 1 Case 2 Case 3 
 
 
 
 
Societal 
importance 
(drivers for 
change) 
Disease Area HIV 
 
Malaria Diabetes 
Patient population Estimated to be up to 35M 
[29] 
220M [35], projected to 
increase to over 500M by 2018 
[36] 
387M, of which 90% is Type 2 
diabetes [43] 
 
Unmet needs 
Treatment regimes complex. 
Managing complexity and 
adherence [30]. 
Access cost for newer 
drugs. 
Product Cost high to patient 
without subsidy.  Significant 
security issues. 
High counterfeit rates in several 
countries [35]. 
Growing prevalence in 
emerging markets, >590M 
patients by 2035 [43]. 
Affordability and access to 
treatment.  
 
Affordability factors 
High cost for new 
combination products.  
Older drugs for least-
developed countries <$1 per 
day [31] 
Subsidy levels, to enable 
consumer affordability are 
currently high at ~ 90% [37].  
Global funding for malaria, 
US$2.3B (in 2011)  
Major healthcare cost  
In 2014, expenditure reached 
US $612 billion [43] 
Operational 
Data 
Volumes (current) 5-100 tonnes/a 200-250 tonnes/a  
[38] 
30,000 tonnes/a [44] 
Basic financials: cost; 
revenues; margin 
Older drugs $400-1000/kg. 
Opportunities to reduce 
costs [32], [33]. 
Newer drugs >$5000/kg 
Plant-derived API costs at 
$350-1200/kg.  
API costs using a bio-
processing route $400/kg [39]  
Generic; Estimated API costs 
at $5-15/kg 
 
SKU mix Multiple classes of drug [30]. 
Over 50 combinations [31] 
>100 million packs/a [2] 
Multiple combinations [35]  
 
Several generic brands; 9 
FDA approved combinations 
[45] and various pack sizes 
Inventory Est. Final product 3-6 
months  
Est. Final product 3-6 months Est. Final product 3-6 months 
CapEx delta 
(batch -> continuous) 
Much existing capacity in 
place. Potential 
opportunities for reduced 
Capex in continuous 
formulation of combinations 
Potential capex savings if new 
capacity is required, based on 
design calculations 
 
Alternative chemistry, with 
improved kinetics [46] enables 
continuous process to deliver 
increased capacity at lower 
capex. 
 
Quality/waste High quality API required to 
control combination 
formulations.  Batch API 
process have relatively low 
yields and high waste. (10s 
kg/kg output) 
Current process highly variable 
quality and very low yields 
(cultivation and extraction) and 
high waste (100s kg/kg output) 
[38] 
 
Current processes have high 
yields and purity (>95%) [47] 
 
 
Processing 
model 
Current Multi-stage batch. 
Opportunities to reduce cost 
[29], 
No. of drugs / regimens 
complex [30] 
Plant extraction / purification 
and multi-stage batch [38].  
Delivery performance poor [36] 
Very simple batch process.   
Low cost already available 
[47] 
Future Potential for continuous API 
and continuous secondary. 
Service improvement 
opportunities [34] 
Several alternative synthetic 
routes with improved kinetics 
enable continuous API 
processing [38].  
Potential for continuous 
secondary processing [40], 
[41], [42] 
High probability to be 
amenable to continuous API 
[46] and alternative 
formulation process enables 
secondary continuous 
processing [48] 
Potential 
opportunity 
Evaluation summary 
of opportunities from 
continuous 
manufacturing 
Improved API control to 
enable new formulation 
opportunities.  Potential for 
new combination products to 
improve adherence and 
treatment 
 
Potential for improved quality 
and supply reliability, and to 
reduce overall product cost.  
 
Reduced capital cost for 
increased capacity required.  
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Table 3. Potential benefits of continuous manufacturing in the pharmaceutical industry  
(Key: ++ Significant opportunity; + some opportunity; = Neutral / borderline; - penalty in moving to continuous) 
 
Impact variable Case 1 Case 2 Case 3 
 
Δ Inventory 
+  
Complexity lies in number of 
combinations used in therapy.   
Current batch processing 
results in high inventory.  
Continuous processing better 
matched to demand, can 
reduce inventory in 
manufacturing and supply 
chain 
++  
Current processes rely on 
annual harvesting, 
bioprocessing and batch 
processing.  Continuous 
processing can significantly 
reduce inventory.   
+  
Likely to have benefits from 
better E2E management given 
potential scale of supply 
required in future 
 
Δ Lead time supply 
+ 
High variety of combinations. 
Cycle time opportunities (as 
above) 
+ 
Opportunity to reduce overall 
lead-time to final product 
(from 10s of months to weeks) 
+ 
API content high. Having a 
stable supply offers potential for 
downstream improvement  
 
Δ Lead time to market 
-  
Priority regulatory review (for 
new products) may limit 
opportunities in primary 
+ 
Opportunities for continuous 
secondary to develop 
combination products 
= 
Opportunities only if new 
derivatives are developed. 
Some opportunities for 
continuous secondary to 
develop new combination 
products 
= 
API is already generic.  
In terms of clinical trials, not 
relevant unless part of a new 
combination.  
Smaller footprint of a continuous 
plant could provide shorter lead 
time to new capacity 
 
Δ Scale-up 
+ 
Further process development 
required before scale-up. 
Continuous processing may 
enable better API quality 
control for formulation 
(especially for high drug 
loading products)  
- 
The complexity of synthetic 
routes may limit opportunities  
+ 
Further process development 
required before scale-up. 
Continuous processing may 
enable better API quality 
control on scale-up of that 
process.   
 
++ 
Further process development 
required before scale-up. 
Opportunities exist as global 
capacity is projected to double.  
Continuous plant for both API 
and formulation should be 
feasible for a lower footprint and 
reduce capital cost 
 
 
Δ Volume flexibility 
(mix/volume) 
+ 
Volume (flexibility) and mix 
demands create opportunities 
for both API and secondary 
formulation.   Continuous 
formulation offers possibility of 
new ways to manages 
volume/mix 
+ 
High volume with relatively 
stable demand. Potential for 
more combinations in future to 
address drug resistance will 
add to mix.  Continuous 
formulation may enable better 
control. 
+ 
Demand steadily growing. High 
volume flexibility with limited mix 
 
Δ Process control; reliability; 
safety 
+ 
Continuous processing may 
enable better API quality 
control for high drug-load 
combination products 
 
 
+ 
Opportunities to remove 
significant solvent use (in 
extraction) and improve 
overall process reliability 
= 
Currently a very simple process. 
As it is a large volume process, 
continuous may offer 
opportunities to reduce in-
process solvent and reagent 
inventories 
 
Δ Quality; purity; counterfeit 
+ 
Continuous processing should 
enable better API quality 
control and consistency    
Products typically have high 
drug loading, so API quality 
and physical properties are 
more important 
 
+ 
Continuous processing should 
enable better API quality 
control and more consistent 
purity.   
Continuous printing 
technologies and ‘serialisation’ 
offer solutions to counterfeiting 
 
= 
Very simple existing process, 
with high yield and quality.  
 
 
Δ Yield 
= 
Further analysis required on 
potential delta v. batch 
processing with respect to 
overall yield  
++ 
Significant Opportunities to 
use continuous processes to 
recover waste-streams and 
improve overall yield 
= 
Yield already high circa. 96%, 
limited opportunity for further 
improvement 
Δ IP protection/ 
extension/counterfeit 
+ 
Opportunities for IP protection 
and counterfeit prevention 
+ 
Significant counterfeit 
prevention opportunity in 
packaging 
 
+ 
API off patent with multiple 
suppliers. Continuous secondary 
may offer new IP 
 
Δ Cost (process/ 
packaging/transport) 
+ 
Opportunities in formulation 
and secondary processing due 
to wide number of variants, 
combinations, strengths, pack 
sizes and country 
requirements 
++ 
A major driver for WHO as 
current subsidy levels remain 
high (>90% )[21] 
= 
Costs already low. Some 
opportunity to improve 
performance in e.g. continuous 
pack around flexibility and 
service 
 
Δ Investment cost 
+ 
Potential for lower investment 
cost for additional secondary 
capacity and packaging 
+ 
Continuous processes have 
fast kinetics, enabling smaller 
plant size. Potential for lower 
+ 
Potential for lower investment 
cost for more capacity 
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investment cost for more 
capacity 
 
Δ Fiscal/tax 
= 
Potential opportunity with 
NGOs, governments for major 
programmes  
= 
Potential opportunity with 
NGOs, governments for major 
programmes 
+ 
Potential opportunity to locate 
manufacture in local markets 
 
Δ Environmental 
impact/solvent 
+ 
Opportunity to reduce reagent 
and solvents use with 
continuous processing 
 
++ 
Solvents (and environmental 
impact) a major issue in 
current extraction process.  
Combinations of 
bioprocessing and continuous 
processing could potential 
reduce solvent demand by 80-
90%. 
 
+ 
Some opportunities on specific 
continuous technology 
adoptions requirements and 
routes to manufacture.   
Opportunity to further reduce 
residual solvent to improve API 
quality 
 
Δ Viability/adaptability 
= 
Limited studies on alternative 
processes to date. Limited 
work on continuous 
formulation processes  
+ 
Several continuous schemes 
have been developed (30) 
which demonstrate potential 
feasibility and benefits 
+ 
Ease of manufacture (2-step 
chemistry) - amenable to smaller 
continuous plants 
 
Δ Asset utilisation 
= 
Continuous API likely to be 
dedicated v. multi-purpose 
batch, so potential for lower 
asset utilisation if volume 
flexibility is high  
 
= 
Continuous API likely to be 
dedicated v. multi-purpose 
batch, so potential for lower 
asset utilisation if volume 
flexibility is high 
= 
Amenable to have multiple 
smaller continuous plants close 
to target (new) markets 
 
 
 
 
 
(iv) Systems Analysis Analytical Framework 
The analytical framework presented in this paper examined the interactions between the sub-systems in Pharma 
for the three cases, representing dissimilar product examples to demonstrate the utility of the approach.  
 
In this paper, limitations of space constrain the full graphical presentation of the comparative analysis. However, 
figures 4 and 5 set out impact variables for the three case products in terms of cycle time v. %inventory for 
primary/secondary processing and %Inventory v. service in terms of E2E supply respectively. In assessing the 
specific continuous interventions for the three cases presented and the potential scale of opportunities across the 
E2E supply chain [1], significant reductions of up to 50%, in terms of cycle time (starting materials to packed 
product) and >65% reductions of inventory (within primes) are achievable. This, in turn, improves service levels 
to the patient through the emergence of more demand-driven supply models [1].  
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Figure 4 – Primary/secondary continuous processing – specific benefits for the 3 cases in terms of improved 
cycle time  
 
 
 
 
 
 
 
Figure 5. E2E supply through continuous processing – specific benefits for the three cases in terms of inventory 
and service  
 
 
 
Table 4 summarises the analysis for continuous processing across the three case product groups, using the 
analytical framework in conjunction with considerations of business context and technological readiness.  
 
Batch	Con nuous	
% Inventory/Cost
Cycle time
(months)
10
20
30
Case 3
• Beneﬁts here in terms of % inventory (and 
management of E2E supply) as opposed to cycle 
times, given potential scale of future supply 
requirements
Case 2
• Current processes reliant on annual harvesting 
      (c. 18 months) and batch processing. 
• Opportunity for continuous synthesis and bio-
processing to signiﬁcantly reduce overall lead-
time to ﬁnal product (from 10s of months to 
weeks) with signiﬁcant implications for cycle time
Case 1
• Minimum batch size requirements have resulted in 8 month delays between an 
initial order and production for low volume, niche products
• Continuous crystallisations of API, better particle size control, coupled with 
continuous formulation offer new ways of managing complexity of volume, 
combinations and SKU mixes – eliminating the batch size requirements
• Signiﬁcant opportunity to reduce overall cycle times by ~50% 
Batch/current
Inventory	
(%)	
Service		
%	on	 me	in-full	(%OTIF)	
Continuous/future
Case 3
• Continuous secondary processing to drive 
signiﬁcant service level beneﬁts through 
smaller footprints enabling local supply, 
closer-to-market
Case 2
• Continuous formulation increasing the bioavailability of APIs would 
signiﬁcantly reduce inventory, number of SKUs and overall cost of 
goods. 
• Alternative continuous processing-driven network design options 
are enabling potential for signiﬁcant improvements in terms of 
supply, distribution, and improved security – reducing the ‘pill 
burden’, leading to better treatment adherence and service levels
Case 1
• Manufacturers tend not carry a lot 
of inventory to avoid undeliverable 
stock that may fall below e.g. 
country requirements. 
• Suppliers instead postpone 
production until conﬁdence exists 
that there is enough demand to 
merit production of a full batch.
• Continuous processing has the 
potential to improve service levels 
by promoting a true ‘made-to-order’ 
model – eliminating high %-based 
shelf-life requirements, production 
delays and potential for stock-outs
Typically 
> 90% to 
distributor 
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Table 4. Analytical framework outputs of potential for continuous processing, coupled with business context 
weighting and technology feasibility – Cases 1-3 
 
Parameters Case 1 Case 2 Case 3 
Analytical Framework 
Outputs (delta) 
 Volume v. Variety 
 Revenue and Operating costs v. 
Time 
 Investment Cost v. Time 
 Quality/Yield v. Inventory/Cost 
 Cycle Time v. Inventory/Cost 
 SKU Variety v. Volume 
 Inventory (%) v. Service (On-
Time In –Full/Availability) 
 
Driven by a complex 
number of variants: wide 
range of regimens, 
volumes, combinations, 
strengths, pack sizes 
and countries 
 
 
Driven by 
opportunities to 
significantly reduce 
lead-time and increase 
service levels.  
 
 
Driven by the need 
for significant 
additional capacity. 
 
 
 
 
 
 
Business  
Context Weighting 
 
i.e. potential Manufacturing 
Conversion savings (% of NPS) plus 
SC Inventory saving as % continuous 
manufacturing capex 
 
Uncertainty as several 
new HIV therapies are in 
development, and may 
be ‘fast tracked’ if they 
show good performance 
 
 
 
Stable demand profile 
likely to remain at 200-
300 tonnes/a. Driven 
by potential for cost 
and inventory 
reduction. 
 
 
Driven by volumes, 
which are predicted 
to double. Potential 
for smaller footprint, 
lower investment 
cost and opportunity 
for local supply. 
 
Process Manufacturing 
Technical feasibility 
 
(Chemistry/ Continuous processing) 
Informed by Technology Roadmaps 
 
Multiple drugs using 
several stages of 
synthesis, which are 
often complex.  
 
 
Several continuous 
processes have been 
developed which have 
demonstrated 
potential benefits 
 
 
Highly amenable, 
driven by ease of 
chemical 
route/manufacture 
 
 
 
 
Specifically, 
 Case 1 may be classed as having medium potential. Whilst there may be opportunities in continuous 
formulation and tableting processing due to high drug-loading and drug-switching requirements, there 
remains large uncertainty with respect to the direction future front-line therapies and specific product 
lifecycle.  
 Case 2 has high potential with opportunities to reduce cost and inventory and improve supply chain 
security.  
 Case 3 has the highest potential for a switch to continuous, with simpler chemistry and a significantly 
growing demand requiring more capacity 
 
  
From a systems integration perspective, all three cases benefit from more integrated flow-through processing. As 
supply network design typically promotes flow-through as a principle of operation, and that continuous processing 
also offers volume flexibility, especially for lower scale production activities, all the continuous processing 
scenarios score favourably against current batch operations.   
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5. DISCUSSION & CONCLUSIONS 
 
This paper extends earlier conceptual developments [25] on the evaluation of continuous processing 
technologies by applying refined concepts to three specific cases that are being actively explored in the sector. 
It first explores the relative attractiveness of continuous vs. batch, and sets out the key factors, from an 
operations/supply-chain perspective, that needs to be considered. These observations are ‘generic’ in nature but 
make the case that continuous should be more prevalent in practice than it has been (in addition to being 
inappropriate in certain instances). The second set of observations, presented here as part of the conclusions, 
refer to the specific case studies and are very specific in nature. The aim is to explore possible options, and only 
in specific cases can priorities be discussed or identified.  
  
The analytical approach has been applied in three case studies within the pharmaceutical sector where 
continuous processing is being actively considered. The analysis identifies reconfiguration opportunities that are 
driven by alternative product-processing innovations using continuous processing. The three specific case 
product groups that were considered represent diverse product-patient categories, where continuous processing 
may benefit a range of new product and patient groups. We conclude that the cases have medium to high 
potential for continuous processing and that case 3 has the highest potential based on the factors of analysis. In 
the three cases analysed, the following assessments were generated.  
 
 Case 1 – Anti-retrovirals (ARVs) case study: may be classed as having medium potential, with specific 
opportunities in continuous crystallisations to enable better API quality control (especially for high drug 
loading products). Similarly, advances in continuous formulation may support product portfolio 
complexity management and drug switching requirements. However, there remains large uncertainty 
with respect to the direction of future front-line therapies and specific product lifecycles.  
 
Discussion: In their recent review paper, Ripin et al. present key procurement and supply chain issues 
that challenge the timely and reliable delivery of ARVs [2]. Here, the opportunities around continuous 
formulation confirm new ways of managing the high complexity of volumes, combinations and SKU 
mixes to enable significant cycle time reductions, given the increasing fragmentation of demand, 
forecasting inaccuracies, shelf-life requirements and high variety of combinations. The current formulary 
list for ARVs is wide-ranging and complex – with each regimen having multiple formulations, with single, 
double or triple fixed-dose combination options. Overall demand continues to be split into smaller and 
smaller entities, by chemical entity, leading to very low treatment volumes. In terms of these very 
specialised drugs, it is becoming more and more difficult for manufacturers to retain profitability [2]. The 
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case is also presented where pooled demand from three sources is required in order to ‘trigger’ 
achievement of the minimum batch size requirements for the product. The process here is lengthy, 
where examples have been reported of 8-month delays between and initial order and the initial batch 
production run. It is feasible to eliminate this lead-time and improve security of supply, through adopting 
smaller volume runs through more continuous routes.  
In addition to the extensive drug-switching requirements for HIV as part of treatment regimes, 
driving product variants and complexity, the high requirements on shelf-life and a rather atypical tender 
model (where market specific stock is made to contract order) means manufacturers will typically not 
carry a lot of inventory to avoid undeliverable stock that may fall below e.g. country requirements. 
Service levels are artificially high (typically > 90% to distributor) as suppliers tend to postpone any 
production until confidence exists that there is enough demand to merit a full batch - often leading to 
delays, stock-outs and less than ideal service levels [2]. In summary, continuous processing has the 
potential to improve service levels by reducing % inventory, eliminating minimum batch size 
requirements and safety stocks - enabling a more ‘made-to-order’ contract model. 
 
 
 Case 2 – Anti-malarial Artemisinin Combination Therapies (ACTs) case study: has high potential, with 
opportunities to reduce cycle times and inventory, by adopting continuous processes that also reduce 
solvent use. Several competing technology developments are being considered with maturing 
technology readiness levels, which suggest promising routes to commercialisation are possible. 
 
Discussion: The current batch process involves cultivation (e.g. planting, growing, harvesting), then 
extraction using solvents, which is costly, and poses safety, environmental and product quality risks 
[38]. The total cycle time from planting to shipping is normally in excess of 14 months. A bioprocessing 
route has also been developed and commercialised (and qualified as an alternative source for Case 2-
based derivatives in 2013 by the WHO). However the cost of goods remains high and is similar to plant-
derived sources ($350-400/kg). Capacities via this route are in the range of 50-60MT (It is estimated 
that global capacity will remain ~200MT). On-going studies have outlined a series of continuous and 
hybrid routes, from synthesis (cutting lead times in the range of 30-90 days, currently, to 5-10 days) 
through to pack and distribution - with the potential of reducing overall cycle times (raw materials to 
pack) to 10s of weeks [3].  
Advances in continuous formulation to increase the bioavailability of APIs would significantly 
help reduce overall cost of goods and improve treatment adherence. The ‘pill burden’ may be 
significantly reduced, thereby, maximising the impact of benefit for patients and health providers. 
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Alternative network design options, exploring new technologies (e.g. inkjet printing) with respect to pack 
design [26], have a significant opportunity in terms of supply chain and distribution, improving security 
and enabling health agencies to access better data.  
 
 
 Case 3 – Diabetes drug case study: has the highest potential for a switch to continuous granulation 
supporting smaller plant footprints with associated capital cost reductions. The simpler chemistry 
involved in this case study and a significantly growing demand (requiring more capacity), where volume 
projections suggest a doubling of demand by 2035; contribute to a potentially attractive batch-to-
continuous transformation agenda.  
 
Discussion: Having uninterrupted supply offers downstream inventory improvement, in the case of case 
3, as opposed to cycle time gains presented for cases 1 and 2. As demand continues to increase 
(double-digits year-on-year), there are significant benefits in terms of % inventory and the management 
of E2E supply - given the volume and scale flexibilities afforded by continuous processing [1], [27], [28]. 
 
 
The case studies are exploratory in nature and seek to demonstrate a methodology for identifying potential 
opportunity areas. The analysis suggests that the methodology can help to reveal reconfiguration opportunities 
that support re-integration of these sub-systems and deliver enhanced business performance that can also have 
societal benefits. In reviewing the assessments emerging from the analysis, the discussions above suggest the 
initial conclusions from this study are broadly supported. This further underpins the conclusions from the 
analytical approach set out above.   
 
In conclusion, previous research studies confirm that many industrial systems comprise of semi-independent 
sub-systems that have evolved over extended time periods but have then become part-disconnected, operating 
as silos of activity with independent governance and coordination mechanisms [17], [25]. In many cases, the 
regulatory frameworks ‘lock-in’ this structural development. An analytical framework, applicable to multiple 
industrial contexts is presented and applied which considers reconfiguration opportunities that adopt a systems 
perspective rather than incremental optimisation at the sub-system level. At a broader level, the study identifies 
the potential to reconfigure and re-integrate sub-systems by enabling a deeper understanding of the drivers of, 
and interactions between, the main sub-systems that make up complex, multi-tier supply chains.   
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6. LIMITATIONS AND FUTURE WORK 
 
The work is part of an on-going research agenda that seeks to develop next generation Pharmaceutical supply 
chains. This involves extending the preliminary analysis conducted for selected patient populations and product-
process archetypes identified as having attractive business/value propositions and promising technological 
feasibility. The application of the methodology in three exploratory cases is used to demonstrate utility and some 
level of generalisability.  Further case studies would indeed be expected (and are planned) as part of an 
extended testing regime. Consideration of the behavioural changes and dynamic capabilities required to make 
the transformation to continuous processing manufacturing models will be developed as part of future activity.  
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Appendix A: Expert informants, by role, and their contribution to the 3 case studies 
 
 
Interviewee 
/Sources 
 
Role/contribution area 
 
Organisation 
 
 
A 
 
Former head of Global supply chain  
- ARVs 
 
 
Multi-national Pharma 
 
B 
 
 
Former head of Global supply chain  
- anti-Malarial products 
 
 
Multi-national Pharma 
 
C 
 
Former supply chain/technical expert 
- anti-Malarial products 
 
 
Multiple, including Malaria Medicines 
Ventures (MMV) and Assured 
Artemisinin Supply System (A2S2) 
 
 
 
D 
 
Continuous flow technologies – 
specialising in anti-Malarial products 
 
 
Academia 
 
E 
 
 
Continuous manufacturing technologies – 
diabetes context as part of this study 
 
 
 
Multiple Academia 
 
F 
 
Global supply chain and strategy – 
diabetes context as part of this study 
 
 
 
Multi-national Pharma 
 
